Humacyte (HUMA) Accumulated Expenses (2020 - 2026)
Humacyte (HUMA) posted quarterly Accumulated Expenses of $8.7 million for Q1 2026, down 10.56% year-over-year from $9.7 million in Q1 2025, and down 17.68% quarter-over-quarter from $10.5 million in Q4 2025.
Humacyte (HUMA) Accumulated Expenses (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Accumulated Expenses for 7 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 10.56% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (down 10.56% YoY), while the FY2025 annual figure was $10.5 million, up 68.86% from the prior year.
- Accumulated Expenses slipped to $8.7 million in Q1 2026 per HUMA's latest filing, from $10.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $11.2 million in Q3 2024 and bottomed at $173000.0 in Q1 2022.
- Historically, Accumulated Expenses has averaged $7.2 million across 5 years, with a median of $8.7 million in 2026.
- Annual changes were most pronounced in 2023 — Accumulated Expenses surged 5441.04% — and 2024, when it plunged 33.17%.
- Humacyte's Accumulated Expenses stood at $7.1 million in 2022, then surged by 31.4% to $9.3 million in 2023, then plunged by 33.17% to $6.2 million in 2024, then surged by 68.86% to $10.5 million in 2025, then decreased by 17.68% to $8.7 million in 2026.
- Business Quant data shows HUMA's Accumulated Expenses at $8.7 million in Q1 2026, $10.5 million in Q4 2025, and $10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.27 Mn |
| Mar 31, 2026 | 8.68 Mn |
| Dec 31, 2025 | 10.54 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 9.19 Mn |
| Mar 31, 2025 | 9.70 Mn |
| Dec 31, 2024 | 6.24 Mn |
| Sep 30, 2024 | 11.15 Mn |
| Jun 30, 2024 | 8.95 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Dec 31, 2023 | 9.34 Mn |
| Sep 30, 2023 | 9.59 Mn |
| Jun 30, 2023 | 6.57 Mn |
| Mar 31, 2023 | 6.41 Mn |
| Dec 31, 2022 | 7.11 Mn |
| Sep 30, 2022 | 173,000.00 |
| Jun 30, 2022 | 173,000.00 |
| Mar 31, 2022 | 173,000.00 |
| Dec 31, 2021 | 173,000.00 |
| Sep 30, 2021 | 145,000.00 |